Four-year outcomes with third-generation centrifugal left ventricular assist devices in an era of restricted transplantation

Faruk Özalp, Sai Bhagra, Catriona Bhagra, Tanveer Butt, Bandigowdanapalya Ramesh, Nicola Robinson-smith, Neil Wrightson, Gareth Parry, Massimo Griselli, Asif Hasan, Stephan Schueler, Guy A. MacGowan

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Objectives: Third-generation ventricular assist devices (VADs) are associated with improved outcomes, though in recent clinical trials bridge-to-transplant (BTT) rates are ∼30% at 6 months, so that transplantation can be used as a 'bail out' for serious complications. In the UK, there was a significant reduction in heart transplantation rates over the last decade, so that transplantation from VADs is much less frequent. The objective of this study was to determine outcomes and their predictors in this situation of low BTT rates, and as patients were exposed to long-term support, the incidence and outcomes of VAD thrombosis. Methods: We analysed outcomes for 102 consecutive patients between 2009 and 2013 (mean age 47 ± 13; VentrAssist n = 6 and HeartWare n = 96). The median duration of support was 462 ± 426 days. Results: Survival rates on the device were 75 and 66% at 1 and 2 years, respectively. Older age and more acute INTERMACS groups were significantly related to reduced survival within the first 90 days (P = 0.030 and 0.010, respectively). Poor preoperative right ventricular (RV) function had a negative effect on survival after 1 year (P = 0.009), though not earlier. VAD thrombosis (n = 24 HeartWare and n = 1 VentrAssist) occurred at 0.18 events per patient-year for HeartWare and 0.07 for VentrAssist devices at a median time of onset at 404 ± 281 days. There was no significant effect of VAD thrombosis on survival. Only 14 of 102 patients were transplanted at a median of 334 ± 347 days, and only 3 were transplanted within the first 6 months. Conclusions: Third-generation left ventricular assist device implants with a low rate of transplantation have similar survival to destination therapy, and are susceptible to long-term complications of VAD thrombosis and right heart failure.

Original languageEnglish (US)
Article numberezu258
Pages (from-to)e35-e40
JournalEuropean Journal of Cardio-thoracic Surgery
Issue number3
StatePublished - Sep 2014
Externally publishedYes


  • Outcomes
  • Thrombosis
  • Transplantation
  • Ventricular assist device


Dive into the research topics of 'Four-year outcomes with third-generation centrifugal left ventricular assist devices in an era of restricted transplantation'. Together they form a unique fingerprint.

Cite this